Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 1,130.7	$ 1,308.0
Marketable securities	2,454.7	2,120.5
Accounts receivable, net	1,395.1	1,227.0
Due from anti-CD20 therapeutic programs, net	315.1	314.5
Inventory	964.6	893.4
Other current assets	941.1	836.9
Total current assets	7,201.3	6,700.3
Marketable securities	3,189.8	2,760.4
Property, plant and equipment, net	2,258.9	2,187.6
Intangible assets, net	4,012.2	4,085.1
Goodwill	2,917.9	2,663.8
Investments and other assets	1,094.6	1,107.6
Total assets	20,674.7	19,504.8
Current liabilities:
Current portion of notes payable and other financing arrangements	4.9	4.8
Taxes payable	496.5	208.7
Accounts payable	271.3	267.4
Accrued expenses and other	2,003.9	2,096.8
Total current liabilities	2,776.6	2,577.7
Notes payable and other financing arrangements	6,535.6	6,521.5
Long-term deferred tax liability	117.8	124.9
Other long-term liabilities	916.6	905.8
Total liabilities	$ 10,346.6	$ 10,129.9
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	$ 0.0	$ 0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	18.4	0.0
Accumulated other comprehensive loss	(259.3)	(224.0)
Retained earnings	13,179.3	12,208.4
Treasury stock, at cost	(2,611.7)	(2,611.7)
Total Biogen Inc. shareholders’ equity	10,326.8	9,372.8
Noncontrolling interests	1.3	2.1
Total equity	10,328.1	9,374.9
Total liabilities and equity	$ 20,674.7	$ 19,504.8